Host A2B receptors promote carcinoma growth

Neoplasia

Volumn 10, Issue 9, 2008, Pages 987-995

  Ryzhov, Sergey ^a   Novitskiy, Sergey V ^a   Zaynagetdinov, Rinat ^a   Goldstein, Anna E ^a   Carbone, David P ^a   Biaggioni, Italo ^a   Dikov, Mikhail M ^a   Feoktistov, Igor ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2B RECEPTOR; CD45 ANTIGEN; VASCULOTROPIN; PTPRC PROTEIN, MOUSE; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL POPULATION; CELL SURVIVAL; CONTROLLED STUDY; FLOW CYTOMETRY; HOST CELL; LEWIS CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; ANIMAL; COMPARATIVE STUDY; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

ANIMALS; ANTIGENS, CD45; CARCINOMA, LEWIS LUNG; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, ADENOSINE A2B; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 50949115838     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08478     Document Type: Article

References (37)

1. Linden J (2006). Adenosine metabolism and cancer. Focus on "Adenosine downregulates DPPIV on HT-29 colon cancer cells by stimulating protein tyrosine phosphatases and reducing ERK1/2 activity via a novel pathway". Am J Physiol 291, C405-C406.
2. Lukashev D, Ohta A, and Sitkovsky M (2007). Hypoxia-dependent antiinflammatory pathways in protection of cancerous tissues. Cancer Metastasis Rev 26, 273-279.
3. Blay J, White TD, and Hoskin DW (1997). The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res 57, 2602-2605.
4. s protein-coupled adenosine receptor signaling and lytic function of activated NK cells. J Immunol 175, 4383-4391.
5. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, and Linden ] (2001). International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53, 527-552.
6. Fredholm BB, Irenius E, Kull B, and Schulte G (2001). Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol 61, 443-448.
7. 2B receptors. Pharmacol Rev 49, 381-402.
8. 2 receptors. Mol Pharmacol 43, 909-914.
9. 2B receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma J Clin Invest 96, 1979-1986.
10. 2B adenosine receptors in the U87MG tumor cells. Drug Dev Res 58, 405-411.
11. 2+ signal. Br J Pharmacol 145, 211-218.
12. Phelps PT, Anthes JC, and Correll CC (2006). Characterization of adenosine receptors in the human bladder carcinoma T24 cell line. Eur J Pharmacol 536, 28-37.
13. Rodrigues S, De Wever O, Bruyneel E, Rooney RJ, and Gespach C (2007). Opposing roles of netrin-1 and the dependence receptor DCC in cancer cell invasion, tumor growth and metastasis. Oncogene 26, 5615-5625.
14. 3 adenosine subtype. J Cell Physiol 211, 826-836.
15. Li S, Huang S, and Peng SB (2005). Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int J Oncol 27, 1329-1339.
16. 3 adenosine receptors. Circ Res 92, 485-492.
17. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Simioni C, Leung E, Maclennan S, Baraldi PG, and Borea PA (2007). Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. Mol Pharmacol 72, 395-406.
18. O'Byrne KJ and Dalgleish AG (2001). Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 85, 473-483.
19. Bingle L, Brown NJ, and Lewis CE (2002). The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196, 254-265.
20. Ryzhov S, McCaleb JL, Goldstein AE, Biaggioni I, and Feoktistov I (2007). Role of adenosine receptors in the regulation of angiogenic factors and neovascularization in hypoxia. J Pharmacol Exp Ther 382, 565-572.
21. 2B receptors in angiogenic factor regulation. Circ Res 90, 531-538.
22. 2A adenosine receptors and C/EBPbeta are crucially required for IL-10 production by macrophages exposed to E. coli. Blood 110, 2685-2695.
23. Williams CS, Tsujii M, Reese J, Dey SK, and DuBois RN (2000). Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105, 1589-1594.
24. 2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J Clin Invest 116, 2173-2182.
25. 2A adenosine receptor antagonist. J Pharmacol Exp Ther 276, 398-404.
26. 2B adenosine receptor subtypes. Biochem Pharmacol 55, 627-633.
27. Grant MB, Tarnuzzer RW, Caballero S, Ozeck MJ, Davis MI, Spoerri PE, Feoktistov I, Biaggioni I, Shryock JC, and Belardinelli L (1999). Adenosine receptor activation induces vascular endothelial growth factor in human retinal endothelial cells. Circ Res 85, 699-706.
28. Spychala J (2000). Tumor-promoting functions of adenosine. Pharmacol Ther 87, 161-173.
29. Merighi S, Mirandola P, Varani K, Gessi S, Leung E, Baraldi PG, Tabrizi MA, and Borea PA (2003). A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol Ther 100, 31-48.
30. 2b receptor is highly expressed in human hepatocellular carcinoma. Hepatol Res 36, 56-60.
31. Dirkx AE, Oude Egbrink MG, Wagstaff J, and Griffioen AW (2006). Monocyte/ macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol 80, 1183-1196.
32. Kusmartsev S and Gabrilovich DI (2006). Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 55, 237-245.
33. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, Delgado A, Correa P Brayer J, Sotomayor EM, et al. (2004). Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 64, 5839-5849.
34. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, and Carbone DP (1998). Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92, 4150-4166.
35. Dikov MM, Ohm JE, Ray N, Tchekneva EE, Burlison J, Moghanaki D, Nadaf S, and Carbone DP (2005). Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol 174, 215-222.
36. Huang Y, Chen X, Dikov MM, Novitskiy SV, Mosse CA, Yang L, and Carbone DP (2007). Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hemato-poiesis associated with elevated levels of VEGF. Blood 110, 624-631.
37. 2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci USA 103, 13132-13137.